Medical School, Anhui University of Science and Technology, Huainan, China.
Department of Respiratory Medicine, People's Hospital of Bozhou, Bozhou, China.
Biomed Pharmacother. 2017 Jul;91:1184-1192. doi: 10.1016/j.biopha.2017.05.041. Epub 2017 May 19.
Renal cell carcinoma (RCC) is the most common subtype of kidney cancer. Currently, there is a lack of efficient treatment for RCC. Bicyclol, an anti-hepatitis drug, has been demonstrated to possess anti-tumor properties. However, the effect of bicyclol in RCC remains elusive. Therefore, the aim of this study is to investigate the biological effects of bicyclol on RCC and the underlying mechanisms. The data from this study indicated that bicyclol markedly induced cell apoptosis and cell cycle arrest and increased the production of reactive oxygen species (ROS) in RCC cells. Moreover, bicyclol induced ER stress in a ROS-dependent manner, since the ROS scavenger NAC could block this effect. Taken together, the results of this study provide evidence that bicyclol may serve as a potential therapeutic agent for the treatment of human RCC.
肾细胞癌（RCC）是最常见的肾癌亚型。目前，RCC 的治疗方法效率低下。双环醇是一种抗肝炎药物，已被证明具有抗肿瘤特性。然而，双环醇在 RCC 中的作用仍不清楚。因此，本研究旨在探讨双环醇对 RCC 的生物学效应及其潜在机制。本研究的数据表明，双环醇显著诱导 RCC 细胞凋亡和细胞周期停滞，并增加活性氧（ROS）的产生。此外，双环醇以 ROS 依赖的方式诱导内质网应激，因为 ROS 清除剂 NAC 可以阻断这种作用。综上所述，本研究结果提供了证据表明，双环醇可能作为一种治疗人类 RCC 的潜在治疗剂。
